Bone marrow purging prior to autologous transplantation.
Our data suggest that ex vivo bone marrow purging using monoclonal antibodies (MoAbs) and sheep-anti-mouse immunobeads (SAM beads) prior to autologous bone marrow transplantation (ABMT) allows satisfactory tumor cell reduction without critical stem cell losses. Nevertheless, there is only a reduction but no elimination of tumor cells. The consequences will have to be clinically discussed.
Zingsem
J
J
Abteilung für Transfusionsmedizin, Universitätsklinik Erlangen, Erlangen-Nürnberg, BRD.
Stahlhut
K
K
Serke
S
S
Zeiler
T
T
Weisbach
V
V
Zimmermann
R
R
Siegert
W
W
Eckstein
R
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016465:Bone Marrow Purging / Q000295:instrumentation*; D016026:Bone Marrow Transplantation / Q000295:instrumentation* / Q000473:pathology; D002051:Burkitt Lymphoma / Q000473:pathology / Q000601:surgery; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000601:surgery*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000473:pathology / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000601:surgery*; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000601:surgery; D014182:Transplantation, Autologous; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal